Author: Jakob Hohenberger

Insight One – The beginning of Celeris Therapeutics

Insight One – The beginning of Celeris Therapeutics

  In this podcast Amir Amanzadi, Head of Computational Chemistry, talks to Christopher Trummer, CEO and Co-Founder, and Jakob Hohenberger, COO/CFO and Co-Founder, about the beginning of Celeris Therapeutics. Insight One The beginning of Celeris Therapeutics (this episode) What role does AI play in biomolecular interactions? What are degraders? Why degraders, and what’s the impact? […]

Read more